Stelios Papadopoulos Sells 10,000 Shares of Exelixis, Inc. (EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Stelios Papadopoulos sold 10,000 shares of Exelixis stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $25.40, for a total transaction of $254,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stelios Papadopoulos also recently made the following trade(s):

  • On Monday, September 18th, Stelios Papadopoulos sold 72,210 shares of Exelixis stock. The shares were sold at an average price of $27.76, for a total transaction of $2,004,549.60.
  • On Tuesday, September 19th, Stelios Papadopoulos sold 200,000 shares of Exelixis stock. The shares were sold at an average price of $27.68, for a total transaction of $5,536,000.00.

Shares of Exelixis, Inc. (NASDAQ:EXEL) opened at 24.47 on Friday. The stock has a market capitalization of $7.19 billion, a price-to-earnings ratio of 123.59 and a beta of 1.97. The firm’s 50 day moving average is $27.08 and its 200 day moving average is $23.49. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $29.50.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. During the same period last year, the company earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 173.1% on a year-over-year basis. On average, equities analysts predict that Exelixis, Inc. will post $0.27 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Stelios Papadopoulos Sells 10,000 Shares of Exelixis, Inc. (EXEL) Stock” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.truebluetribune.com/2017/09/24/stelios-papadopoulos-sells-10000-shares-of-exelixis-inc-exel-stock.html.

A number of equities analysts recently weighed in on EXEL shares. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. SunTrust Banks, Inc. started coverage on shares of Exelixis in a research report on Thursday, July 13th. They issued a “buy” rating and a $33.00 price objective on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Exelixis in a research report on Tuesday, September 12th. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Exelixis has an average rating of “Buy” and an average target price of $26.51.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc increased its holdings in shares of Exelixis by 1.3% during the first quarter. Legal & General Group Plc now owns 84,763 shares of the biotechnology company’s stock valued at $1,834,000 after purchasing an additional 1,078 shares during the period. Aperio Group LLC increased its holdings in shares of Exelixis by 2.7% during the second quarter. Aperio Group LLC now owns 58,345 shares of the biotechnology company’s stock valued at $1,437,000 after purchasing an additional 1,514 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of Exelixis by 7.0% during the second quarter. Teacher Retirement System of Texas now owns 23,251 shares of the biotechnology company’s stock valued at $573,000 after purchasing an additional 1,517 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Exelixis by 14.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 1,838 shares during the period. Finally, Meeder Asset Management Inc. increased its holdings in shares of Exelixis by 26.6% during the second quarter. Meeder Asset Management Inc. now owns 9,957 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 2,091 shares during the period. 79.20% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply